Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 32101663

Pembrolizumab for Early Triple-Negative Breast Cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2020 Feb 27
First author
Schmid P

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2020 Apr;17(4):196. doi: 10.1038/s41571-020-0349-3.
    note
    Source null
    related pmid
    32127649
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2020 Apr;21(4):e183. doi: 10.1016/S1470-2045(20)30154-6.
    note
    Source null
    related pmid
    32145769
    relationship
    Comment in
  3. citation
    Strahlenther Onkol. 2020 Sep;196(9):841-843. doi: 10.1007/s00066-020-01641-9.
    note
    Source null
    related pmid
    32561940
    relationship
    Comment in
  4. citation
    N Engl J Med. 2020 Jun 25;382(26):e108. doi: 10.1056/NEJMc2006684.
    note
    Source null
    related pmid
    32579834
    relationship
    Comment in
  5. citation
    Int J Radiat Oncol Biol Phys. 2022 Nov 1;114(3):377-381. doi: 10.1016/j.ijrobp.2022.05.024.
    note
    Source null
    related pmid
    36152640
    relationship
    Comment in

Authors and identifiers

  1. name
    Schmid P
    type
    Author
  2. name
    Cortes J
    type
    Author
  3. name
    Pusztai L
    type
    Author
  4. name
    McArthur H
    type
    Author
  5. name
    Kümmel S
    type
    Author
  6. name
    Bergh J
    type
    Author
  7. name
    Denkert C
    type
    Author
  8. name
    Park YH
    type
    Author
  9. name
    Hui R
    type
    Author
  10. name
    Harbeck N
    type
    Author
  11. name
    Takahashi M
    type
    Author
  12. name
    Foukakis T
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Schmid P
    type
    Author
  2. name
    Cortes J
    type
    Author
  3. name
    Pusztai L
    type
    Author
  4. name
    McArthur H
    type
    Author
  5. name
    Kümmel S
    type
    Author
  6. name
    Bergh J
    type
    Author
  7. name
    Denkert C
    type
    Author
  8. name
    Park YH
    type
    Author
  9. name
    Hui R
    type
    Author
  10. name
    Harbeck N
    type
    Author
  11. name
    Takahashi M
    type
    Author
  12. name
    Foukakis T
    type
    Author
bibliography ids
  1. nci-bib-0de26b219a1266700dda6bba
book metadata
content sha256
5c2aeb4e1ed1ac0868c3b58443edc22437d7fb8db64cf3be5351fc7c1bf0b50a
document type
citation
dois
  1. 10.1056/NEJMoa1910549
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:32101663
immutable id
pubmed:32101663@5c2aeb4e1ed1ac0868c3b58443edc22437d7fb8db64cf3be5351fc7c1bf0b50a
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
9
name
The New England journal of medicine
nlm unique id
0255562
pages
810-821
volume
382
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2020 Apr;17(4):196. doi: 10.1038/s41571-020-0349-3.
    note
    Source null
    related pmid
    32127649
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2020 Apr;21(4):e183. doi: 10.1016/S1470-2045(20)30154-6.
    note
    Source null
    related pmid
    32145769
    relationship
    Comment in
  3. citation
    Strahlenther Onkol. 2020 Sep;196(9):841-843. doi: 10.1007/s00066-020-01641-9.
    note
    Source null
    related pmid
    32561940
    relationship
    Comment in
  4. citation
    N Engl J Med. 2020 Jun 25;382(26):e108. doi: 10.1056/NEJMc2006684.
    note
    Source null
    related pmid
    32579834
    relationship
    Comment in
  5. citation
    Int J Radiat Oncol Biol Phys. 2022 Nov 1;114(3):377-381. doi: 10.1016/j.ijrobp.2022.05.024.
    note
    Source null
    related pmid
    36152640
    relationship
    Comment in
outcomes validated
false
pmid
32101663
provenance
batch id
4c5003fbb78890e89ae1
provider
NCBI PubMed ESummary
record sha256
0508ced6206380df9f74d5af34c79c8619b8409525aa53ca5bd754d89da37c68
response sha256
890389583ce193a9c74e19c63678e418dad2088e82cb704b888b02fcc887d269
retrieved at
2026-09-09T23:47:48.270700+00:00
publication date
display
2020 Feb 27
precision
day
year
2020
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/32101663/
title
Pembrolizumab for Early Triple-Negative Breast Cancer.

Preserved source evidence · Not medical advice